- Bayern hit nine, Real Madrid and Liverpool win as new Champions League kicks off
- Author John Grisham joins bid to save Texas death row inmate
- Venezuela arrests fourth American over alleged 'plot' against Maduro
- 'Happy' Mbappe strikes on Madrid Champions League debut win over Stuttgart
- Man Utd hit Barnsley for seven in League Cup rout
- Dolphins quarterback Tagovailoa facing concussion layoff
- Stylish Liverpool strut past Milan in confident Champions league opener
- Kane scores four as Bayern put nine past Zagreb in the Champions League
- Mbappe strikes on Madrid Champions League debut win over Stuttgart
- More than 3,600 food packaging chemicals found in human bodies
- Harris calls Trump as assassination scare sparks tensions
- Dow edges down from record as some eye a smaller Fed rate cut
- Sommer vows Inter will 'defend with all we have' to stop Haaland
- Report links meatpacking companies to 'war on nature' in Brazil
- Bolivian ex-leader Morales, backers set out on weeklong protest march
- Smith grateful to McCullum for launching his England career
- Arizona to ask court to rule on voting rights
- Villa make perfect start on Champions League return after 41-year absence
- Israeli supply chain infiltration likely behind Hezbollah pager blasts: analysts
- Rodgers backs Celtic to be 'really competitive' in Champions League
- Spacewalk an 'emotional experience' for private astronauts
- Storm Boris toll rises to 22 in central Europe
- Nine dead, 2,800 wounded as Lebanon's Hezbollah hit by pager blasts
- Boeing, union resume talks as strike empties Seattle plants
- Over 3,600 food packaging chemicals found in human bodies
- Australia's Zampa accepts Ashes chances remote as 100th ODI looms
- UN General Assembly debates call for end to Israeli occupation
- Marseille complete signing of French international Rabiot
- Easterby to fill in as Ireland coach while Farrell is with the Lions
- Hezbollah in Lebanon hit by wave of deadly pager blasts
- Postecoglou taken aback by criticism of his second season success claim
- US, European stocks rise on retail sales, rate cut expectations
- Fendi sees Roaring 20s at Milan Fashion Week in challenging times
- Ronaldo's Al Nassr part ways with coach Castro
- Scottish government backs Glasgow to stage troubled 2026 Commonwealth Games
- Storm Boris toll rises to 21 in central Europe
- Instagram, under pressure, tightens protection for teens
- Inflation slows again in Canada to 2%
- US, European stocks rise on eve of Fed rate decision
- EU bans Algerian spread toasted on social media
- Sean 'Diddy' Combs charged with racketeering, sex trafficking
- Trump returns to campaign trail after assassination scare
- Activist urges repatriation of Native Americans dead in Paris 'human zoo'
- US retail sales see slight rise, beating expectations
- US Fed begins two-day meeting set to end with rate cut
- Exploding Hezbollah pagers wound hundreds across Lebanon
- Runners-up Yokohama thrashed 7-3 in AFC Champions League goal fest
- Sean 'Diddy' Combs to plead not guilty to racketeering, sex trafficking
- Jihadist group claims rare attack on Mali capital
- 'I am a rapist,' Frenchman tells trial over mass rape of wife
Moderna mRNA mpox vaccine shows promise in animal study
An experimental Moderna mRNA vaccine for mpox has demonstrated greater effectiveness than current shots in reducing disease symptoms and duration, according to an animal study published in the journal Cell on Wednesday.
It comes amid an outbreak of the disease in Africa -- partly driven by a new variant that emerged in the Democratic Republic of Congo -- which has been declared an international emergency.
Senior author and virologist Jay Hooper from the US Army Medical Research Institute for Infectious Diseases told AFP that researchers were interested in exploring mRNA technology to find a "sweet spot" -- an mpox vaccine that is both highly safe and highly effective.
Vaccines for mpox, previously known as monkeypox, were originally developed to combat smallpox, which has since been eradicated.
The currently licensed JYNNEOS vaccine uses a "live attenuated" virus, meaning the virus has been weakened so it cannot cause disease in humans.
That attenuation also limits its protective efficacy compared to the older ACAM2000 vaccine -- which was however potentially infectious.
In contrast, the mRNA vaccine includes genetic instructions that train the host's immune system to recognize four key viral antigens, which are crucial for the virus to attach to cells.
Moderna uses the same mRNA technology in its highly safe and effective coronavirus vaccine.
In the study, six macaques were vaccinated with the mRNA vaccine, and another six received an equivalent of the currently licensed vaccine.
Eight weeks after their initial dose, all 12 vaccinated macaques were exposed to a lethal strain of mpox. A third group of six unvaccinated macaques was also exposed to the virus.
Researchers monitored the health of the animals over a four-week period, taking blood samples to assess their immune responses.
As anticipated, all vaccinated animals survived, regardless of the vaccine type, while five out of the six unvaccinated animals died.
"But if we focus specifically on the outcomes with the mRNA vaccine, what we saw was quite surprising and exciting," co-senior author Galit Alter, a virologist and immunologist at Moderna, told AFP.
Animals that received the mRNA vaccine experienced less weight loss and developed significantly fewer lesions compared to those given the live attenuated vaccine.
On average, the control group developed up to 1,448 lesions, the group vaccinated with the older vaccine had a maximum of 607 lesions, and the mRNA-vaccinated group had only 54 lesions at most.
Moreover, the mRNA vaccine shortened the period during which the animals exhibited lesions by more than 10 days compared to the MVA vaccine. It also resulted in lower viral loads in both blood and throat swabs, suggesting it could be more effective in reducing transmission.
First author Alec Freyn of Moderna told AFP that serum from the mRNA-vaccinated macaques was also tested against other viruses in the Orthopox family, and it effectively neutralized vaccinia, cowpox, rabbitpox, camelpox, and ectromelia virus.
The vaccine candidate, named mRNA-1769, is now being tested in an early-stage human clinical trial in the UK to assess its safety and immune response.
T.Ward--AMWN